CRBP
Corbus Pharmaceuticals Holdings, Inc.
There isn't enough reported data to score CRBP yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CRBP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
CRBP's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRBP PE Valuation
CRBP has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CRBP Forward outlook
There aren't enough analyst estimates for CRBP to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CRBP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$6.02 | -$0.49 |
| Q2 2026 | -$6.11 | -$1.33 |
| Q1 2026 | -$5.74 | -$1.50 |
| Q4 2025 | -$5.90 | -$2.22 |
| Q3 2025 | -$5.53 | -$0.90 |
| Q2 2025 | -$4.78 | +$0.97 |
| Q1 2025 | -$4.24 | +$2.66 |
| Q4 2024 | -$3.68 | +$6.63 |
CRBP is still losing money, but far less than before: $6.02 per share over the past year, against $53.40 at its worst in late 2020.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CRBP on earnings quality, reporting a profit while its opponent remains loss making.
CRBP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2021 | $97.3K | -92% |
| Q2 2021 | $136.6K | -52% |
| Q1 2021 | $647.8K | -63% |
| Q4 2020 | $658.2K | -74% |
LLY has the stronger quarterly revenue trend. Revenue is down 100% for CRBP versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2021 | -14257% | -11496 points |
| Q2 2021 | -12230% | +1089 points |
| Q1 2021 | -2379% | -683 points |
| Q4 2020 | -3162% | -2105 points |
| Q3 2020 | -2761% | N/A |
| Q2 2020 | -13319% | N/A |
| Q1 2020 | -1696% | N/A |
| Q4 2019 | -1057% | N/A |
CRBP's operating margin was −14257% last quarter, down 11496 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
CRBP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$21.3M | -$5.7M |
| Q2 2026 | -$29.6M | -$13M |
| Q1 2026 | -$25.6M | -$9.2M |
| Q3 2025 | -$15.6M | -$1.6M |
| Q2 2025 | -$16.6M | -$7.7M |
| Q1 2025 | -$16.4M | -$8.5M |
| Q4 2024 | -$10.9M | -$4.9M |
| Q3 2024 | -$13.9M | -$6.8M |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with CRBP at down 64%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
CRBP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.4% | +1.4M shares |
| 1 year | +70% | +8.6M shares |
| 3 years | +398% | +16.7M shares |
| 5 years | +437% | +17M shares |
| Available history | +878% | +18.7M shares |
CRBP has 21M diluted shares, up 70% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CRBP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CRBP Net Leverage
CRBP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CRBP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.5 | Oversold |
| Stochastic | 4.8 | Oversold |
CRBP's weekly RSI is 29 (oversold) and its Stochastic is 5 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CRBP PE vs Healthcare Sector
CRBP has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CRBP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.74 | 28% below |
| 20 week MA | $7.61 | 55% below |
| 50 week MA | $8.42 | 60% below |
| 100 week MA | $9.05 | 62% below |
| 200 week MA | $14.9 | 77% below |
CRBP is in a downtrend: it's below all five of its weekly moving averages, and 77% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CRBP on trend strength, trading above more of its moving averages.
CRBP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $162.3 | $41.7 | -74% |
| 2021 | $41.7 | $21.0 | -50% |
| 2022 | $21.0 | $3.57 | -83% |
| 2023 | $3.57 | $6.04 | +69% |
| 2024 | $6.04 | $12.8 | +111% |
| 2025 | $12.8 | $8.33 | -35% |
| 2026 YTD | $8.33 | $3.41 | -59% |
CRBP's yearly returns have swung widely, from +111% in 2024 to −83% in 2022. It's down 59% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CRBP on returns for 2026, with the stronger performance.